Prediagnostic 25-Hydroxyvitamin D Concentrations in Relation to Tumor Molecular Alterations and Risk of Breast Cancer Recurrence.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
01
10
2019
revised:
12
12
2019
accepted:
27
03
2020
pubmed:
3
4
2020
medline:
16
9
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
Although vitamin D inhibits breast tumor growth in experimental settings, the findings from population-based studies remain inconclusive. Our goals were to investigate the association between prediagnostic plasma 25-hydroxyvitamin D [25(OH)D] concentration and breast cancer recurrence in prospective epidemiologic studies and to explore the molecular underpinnings linking 25(OH)D to slower progression of breast cancer in the Nurses' Health Studies (NHS, Plasma 25(OH)D was measured with a high-affinity protein-binding assay and a radioimmunoassay. We profiled transcriptome-wide gene expression in breast tumors using microarrays. Hazard ratios (HR) of breast cancer recurrence were estimated from covariate-adjusted Cox regressions. We examined differential gene expression in association with 25(OH)D and employed pathway analysis. We derived a gene expression score for 25(OH)D, and assessed associations between the score and cancer recurrence. Although 25(OH)D was not associated with breast cancer recurrence overall [HR = 0.97; 95% confidence interval (CI), 0.88-1.08], the association varied by estrogen-receptor (ER) status ( Our findings support an intriguing line of research for studies to better understand the mechanisms underlying the role of vitamin D in breast tumor progression, particularly for the ER-positive subtype. Vitamin D may present a personal-level secondary-prevention strategy for ER-positive breast cancer.
Sections du résumé
BACKGROUND
Although vitamin D inhibits breast tumor growth in experimental settings, the findings from population-based studies remain inconclusive. Our goals were to investigate the association between prediagnostic plasma 25-hydroxyvitamin D [25(OH)D] concentration and breast cancer recurrence in prospective epidemiologic studies and to explore the molecular underpinnings linking 25(OH)D to slower progression of breast cancer in the Nurses' Health Studies (NHS,
METHODS
Plasma 25(OH)D was measured with a high-affinity protein-binding assay and a radioimmunoassay. We profiled transcriptome-wide gene expression in breast tumors using microarrays. Hazard ratios (HR) of breast cancer recurrence were estimated from covariate-adjusted Cox regressions. We examined differential gene expression in association with 25(OH)D and employed pathway analysis. We derived a gene expression score for 25(OH)D, and assessed associations between the score and cancer recurrence.
RESULTS
Although 25(OH)D was not associated with breast cancer recurrence overall [HR = 0.97; 95% confidence interval (CI), 0.88-1.08], the association varied by estrogen-receptor (ER) status (
CONCLUSIONS
Our findings support an intriguing line of research for studies to better understand the mechanisms underlying the role of vitamin D in breast tumor progression, particularly for the ER-positive subtype.
IMPACT
Vitamin D may present a personal-level secondary-prevention strategy for ER-positive breast cancer.
Identifiants
pubmed: 32238406
pii: 1055-9965.EPI-19-1217
doi: 10.1158/1055-9965.EPI-19-1217
pmc: PMC7284927
mid: NIHMS1581718
doi:
Substances chimiques
Vitamin D
1406-16-2
25-hydroxyvitamin D
A288AR3C9H
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1253-1263Subventions
Organisme : NCI NIH HHS
ID : K99 CA245900
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA166666
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA176726
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176726
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178263
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009001
Pays : United States
Organisme : NCI NIH HHS
ID : U19 CA148065
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Am J Epidemiol. 2008 Mar 15;167(6):653-66
pubmed: 18230679
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
J Clin Endocrinol Metab. 2014 Jul;99(7):2327-36
pubmed: 24780061
Am J Epidemiol. 2011 Sep 15;174(6):642-51
pubmed: 21828371
Nat Rev Cancer. 2007 Sep;7(9):684-700
pubmed: 17721433
Cancer Res. 1997 Sep 1;57(17):3759-64
pubmed: 9288784
Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2186-E2194
pubmed: 28242709
J Steroid Biochem Mol Biol. 2016 Nov;164:90-97
pubmed: 26485663
Breast Cancer Res Treat. 2019 Feb;173(3):667-677
pubmed: 30387004
Clin Cancer Res. 2001 Apr;7(4):1043-51
pubmed: 11309356
J Cell Biochem. 1997 Sep 1;66(3):413-25
pubmed: 9257197
Breast Cancer Res. 2011 May 11;13(3):R50
pubmed: 21569367
Ann Oncol. 2019 May 1;30(5):733-743
pubmed: 30796437
Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
Cancer Res. 1995 Jul 1;55(13):2822-30
pubmed: 7796409
Steroids. 2012 Sep;77(11):1107-12
pubmed: 22801352
J Cell Biochem. 2015 Aug;116(8):1693-711
pubmed: 25736056
Cancer Res. 2016 Sep 15;76(18):5423-30
pubmed: 27530324
Breast Cancer Res Treat. 2015 Jan;149(2):479-87
pubmed: 25543181
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Cancer Res. 2010 Mar 1;70(5):1835-44
pubmed: 20160035
Breast Cancer. 2008;15(1):31-4
pubmed: 18224391
Stat Med. 2016 Jun 15;35(13):2133-48
pubmed: 27133461
J Clin Oncol. 2009 Aug 10;27(23):3757-63
pubmed: 19451439
Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7
pubmed: 16103450
J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11
pubmed: 17368188
BMJ. 2014 Apr 01;348:g1903
pubmed: 24690623
Endocrinology. 2016 Apr;157(4):1341-7
pubmed: 26934299
Prev Med. 2013 Dec;57(6):753-64
pubmed: 24036014
Bone. 2010 Oct;47(4):795-803
pubmed: 20638491
Cancer Res. 2000 Apr 1;60(7):2040-8
pubmed: 10766196
JAMA Oncol. 2017 Mar 1;3(3):351-357
pubmed: 27832250
Breast Cancer Res Treat. 2013 Jun;139(2):529-37
pubmed: 23660948
J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):343-8
pubmed: 20156557
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Eur J Cancer. 2014 May;50(8):1510-21
pubmed: 24582912
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18827-32
pubmed: 23112173
PLoS Genet. 2007 Sep;3(9):1724-35
pubmed: 17907809
Breast Cancer Res. 2017 Sep 12;19(1):108
pubmed: 28899409
J Natl Cancer Inst. 2014 Aug 19;106(8):
pubmed: 25139534
BMJ. 2014 Jun 17;348:g3656
pubmed: 24938302
J Steroid Biochem Mol Biol. 2018 Mar;177:15-20
pubmed: 28746837
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):938-46
pubmed: 20332276
N Engl J Med. 2019 Jan 3;380(1):33-44
pubmed: 30415629
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Nucleic Acids Res. 2012 Sep 1;40(17):e133
pubmed: 22638577
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):798-806
pubmed: 30591591
Br J Cancer. 2014 Aug 26;111(5):976-80
pubmed: 24918818